Jaguar Health

221 articles about Jaguar Health

• U.S. Veterinary Oncologists Participating in a New Survey Prefer Canalevia-CA1 Over the Current Standard of Care

  4/27/2023

  Jaguar Health, Inc. announced the results of a survey of 26 U.S. veterinary oncologists regarding Canalevia-CA1, the company's U.S. Food and Drug Administration conditionally approved prescription drug product for the treatment of chemotherapy-induced diarrhea in dogs.

• Patient Enrollment Surpasses 90% in Jaguar Health's Pivotal Phase 3 OnTarget Trial of Crofelemer for Cancer Therapy-Related Diarrhea

  4/11/2023

  Jaguar Health, Inc. today announced that patient enrollment has surpassed 90% in the Company's pivotal Phase 3 OnTarget clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients.

• Jaguar Animal Health Exhibiting at Veterinary Cancer Society Collaborative Conference for Canalevia-CA1, the Company's FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs

  3/30/2023

  Jaguar Health, Inc. under its Jaguar Animal Health tradename for the veterinary market, announced that the Company is exhibiting at the Veterinary Cancer Society Collaborative Conference, which takes place April 19-22, 2023 in Cancun, Mexico, as part of ongoing promotional activities for Canalevia-CA1.

• Jaguar Health Reports 2022 Financial Results - Prescription Revenues up 179% to $11.9 Million

  3/27/2023

  Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided Company updates and reported consolidated financial results for the year ended December 31, 2022.

• Jaguar Health Announces Time Change for March 27th Investor Webcast to 8:00 AM EDT

  3/24/2023

  Jaguar Health, Inc. announced that the company investor webcast scheduled for Monday, March 27, 2023 to review fourth-quarter 2022 financials and provide corporate updates will now take place at 8:00 a.m. Eastern Daylight Time instead of 8:30 a.m.

• Leading Cancer Patient Advocate Kelly Shanahan, M.D., Joins Jaguar Health's Scientific Advisory Board

  3/23/2023

  Jaguar Health, Inc. and its wholly owned subsidiary Napo Pharmaceuticals announced that Dr. Kelly Shanahan, a former clinician and a metastatic breast cancer patient who is now a full-time independent patient advocate, has joined the Jaguar/Napo Scientific Advisory Board.

• Jaguar Health to Hold Investor Webcast Monday, March 27th at 8:30 AM EDT Regarding Q4 2022 Financials & Corporate Updates

  3/21/2023

  Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Monday, March 27, 2023 at 8:30 a.m. Eastern Daylight Time to review fourth-quarter 2022 financials and provide corporate updates.

• Jaguar Health Celebrates U.N. International Day of Forests with Milestone of Providing Income to 20,000+ People Living in Tropical Rainforest Communities

  3/15/2023

  Jaguar Health, Inc. announced that the Company, in advance of International Day of Forests, which takes place March 21, 2023, has achieved an important milestone related to the health of forest ecosystems, people, and communities in the Peruvian Rainforest.

• Jaguar Health Leveraging AI to Support Patient Access to Mytesi, the Company's FDA-Approved Prescription Drug

  3/13/2023

  Jaguar Health, Inc. today announced that the Company is developing an artificial intelligence-powered web portal for U.S. healthcare professionals to support patient access to Mytesi.

• Jaguar Health to Present at BioTrinity 2023 Conference’s R&D Spotlight on Rare Diseases

  3/2/2023

  Jaguar Health, Inc. today announced that Lisa Conte, the Company's founder, president, and CEO, is scheduled to present at the BioTrinity 2023 conference in London on Tuesday, April 25, 2023 during the R&D Spotlight session on Rare Diseases.

• FDA Grants Orphan Drug Designation to Jaguar Health for Crofelemer for Microvillus Inclusion Disease (MVID), a Second Rare Disease Indication in the US

  2/28/2023

  Jaguar Health today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to crofelemer for the indication of microvillus inclusion disease (MVID).

• Jaguar Health Receives Notice of Allowance for U.S. Patent for Lead FDA Approved Drug Crofelemer

  2/23/2023

  Jaguar Health, Inc. today announced that the Company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application No. 16/617,466, titled Methods And Compositions For Treating Bile Acid Diarrhea.

• Jaguar Health Achieves Approximately 75% Enrollment in Pivotal Phase 3 OnTarget Trial of Crofelemer for Cancer Therapy-Related Diarrhea

  2/21/2023

  Jaguar Health, Inc. today announced that patient enrollment has reached approximately 75% in the Company's pivotal Phase 3 OnTarget clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy, with or without chemotherapy.

• Jaguar Health Regains Compliance with Nasdaq’s Bid Price Requirement - February 8, 2023

  2/8/2023

  Jaguar Health, Inc. today announced that on February 7, 2023 the Company received formal notice from The Nasdaq Stock Market LLC that Jaguar has regained compliance with Nasdaq's minimum bid price requirement.

• Jaguar Health & SynWorld Technologies Mutually Agree to Terminate License and Commercialization Agreement for Canalevia for Treatment of Diarrhea in Dogs in China Given Jaguar’s 2023 Focus on Human Drug Development

  2/1/2023

  Jaguar Health, Inc. and SynWorld Technologies Corporation (SynWorld) today announced that the two companies have mutually agreed to terminate the exclusive license and services agreement executed in June 2022 for the treatment of diarrhea in dogs in the China market with Jaguar's Canalevia® (crofelemer delayed-release tablets) prescription drug product effective January 31, 2023.

• Jaguar Health Engages Former FDA Gastroenterology Division Deputy Director Andrew Mulberg, M.D. to Bolster Company's Regulatory Expertise

  1/30/2023

  Jaguar Health, Inc. (NASDAQ:JAGX) today announced that it has entered into a consulting agreement with Andrew Mulberg, M.D. to enhance the company's regulatory expertise.

• Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 27, 2023

  1/27/2023

  Jaguar Health, Inc. announced that, effective January 19, 2023, the Company granted 7,500 restricted stock units to New Employee 1 and 7,500 RSUs to New Employee 2.

• Jaguar Health Provides Updates Regarding Company's Focus on Rare and Orphan Disease Indications in the U.S. & Europe

  1/26/2023

  Jaguar Health, Inc. today provided updates regarding the Company's focus on rare and orphan disease indications: short bowel syndrome (SBS), microvillus inclusion disease (MVID), and cholera.

• Jaguar Health Announces Completion of Key Milestone in Process of Establishing Indena S.p.A. as a Reliable Approved Crofelemer Manufacturer

  1/25/2023

  Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the required procedure of registering the source of the active pharmaceutical ingredient (API) of crofelemer with the Agenzia Italiana Del Farmaco (AIFA), the Italian Medicines Agency, has been successfully completed.

• Jaguar Health Announces Establishment of Board of Directors for Newly Formed Joint Venture Magdalena Biosciences

  1/23/2023

  Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the board of directors has been established for Magdalena Biosciences, Inc., the joint venture recently formed by Jaguar and Filament Health Corp.